Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268372 · ClinicalTrials.gov registry record · Phase 3
S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT00268372 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 6 participants.
The verdict
NCT00268372, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known whether giving combination chemotherapy together with radiation therapy is more effective than giving cisplatin together with radiation therapy in treating cancer of the oropharynx. PURPOSE: This randomized phase III trial is studying combination chemotherapy and radiation therapy to see how well they work compared to cisplatin and radiation therapy in treating patients with stage III or stage IV cancer of the oropharynx.
Interventions
- DRUG 5-fluorouracil
- DRUG cisplatin
- DRUG docetaxel
- RADIATION radiation therapy
- PROCEDURE surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268372
The ClinicalTrials.gov registry entry for NCT00268372 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 5-fluorouracil is the first listed.
NCT00268372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268372 about?
NCT00268372 is a clinical study titled "S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx". RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemothera...
What is the current status of trial NCT00268372?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2005-12. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00268372?
The interventions under investigation include: 5-fluorouracil (DRUG), cisplatin (DRUG), docetaxel (DRUG), radiation therapy (RADIATION), surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00268372?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.